Related Experiment Video

Updated: Jun 10, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Targeted therapies for non-clear renal cell carcinoma

Eric A Singer1, Gennady Bratslavsky, W Marston Linehan

  • 1Department of Health and Human Services, Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive Bldg 10 Rm 1-5940, Bethesda, MD 20892, USA. singerea@mail.nih.gov

Targeted Oncology
|August 4, 2010
PubMed

Insights

Targeted therapies are revolutionizing kidney cancer treatment, but non-clear cell subtypes remain understudied. This review details targeted treatments for rare kidney cancer histologies, addressing an unmet clinical need.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Advanced and metastatic kidney cancer treatment has advanced with targeted therapies.
  • Clear cell renal cell carcinoma (ccRCC) has many approved agents.
  • Non-clear cell kidney cancer subtypes (papillary, chromophobe, collecting duct) are underrepresented in clinical trials and lack sufficient therapeutic options.

Purpose of the Study:

  • To review targeted therapies for non-clear cell renal cell carcinoma (nccRCC) subtypes.
  • To discuss the unique molecular profiles of nccRCC subtypes and their impact on treatment.
  • To highlight current and future research directions for nccRCC.

Main Methods:

  • Literature review of targeted therapies for nccRCC.
  • Analysis of clinical trials involving nccRCC.
  • Discussion of genetic and molecular characteristics of nccRCC subtypes.

Main Results:

  • Limited targeted therapy options currently exist for nccRCC.
  • Understanding unique molecular profiles is crucial for developing effective treatments.
  • Cytoreductive nephrectomy and neoadjuvant/adjuvant therapies are also reviewed.

Conclusions:

  • There is a critical need for more research and targeted therapies for nccRCC.
  • Personalized treatment strategies based on specific histology are essential.
  • Future research should focus on novel agents and clinical trial designs for these rare subtypes.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...